3.2.2. EQ-5D
At week 10, filgotinib 200 mg-treated patients had a greater LS mean increase from induction baseline in EQ-5D VAS and EQ-5D-5L UK utility scores than placebo-treated patients, in both the biologic-naïve and biologic-experienced populations [all At week 58, patients in the filgotinib 200 mg group experienced LS mean increases from maintenance baseline in EQ-5D VAS and EQ-5D-5L UK utility scores, whereas patients in the respective placebo group experienced LS mean decreases [EQ-5D VAS, 